Avalo Therapeutics, Inc.
AVTX· Nasdaq
Released Aug 14, 2017, after the close
10-Q filed Aug 14, 2017, 45 days after period end · 0001628280-17-008646
| Metric | Q2 2017 | Q2 2016 | Q2 2015 | Q2 2014 |
|---|---|---|---|---|
| Revenue | $157.80K | — | — | — |
| Net Income | -$1.80M | -$3.52M | -$2.91M | -$4.06M |
| EPS Diluted |
Avalo Therapeutics, Inc. · CIK 1534120 · Engraved from SEC EDGAR
| -$0.14 |
| -$0.41 |
| -$4.48 |
| -$6.39 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.